Speciality: Oncology
Description:
Welcome to an insightful discussion on the critical topic of Cost Burden and Burden of Hospitalization for Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) Patients. Esteemed experts Dr. Pawan Kumar Singh, Dr. Roshan Dikshit, Dr. Manisha Jain, and Dr. Avriti Baveja delve into the multifaceted challenges faced by patients and healthcare systems. The conversation sheds light on the financial, emotional, and logistical strains of prolonged hospitalization, recurring treatments, and the socioeconomic disparities impacting access to advanced therapies. This session is a must-watch for healthcare professionals, policymakers, and caregivers seeking to understand the real-world implications of managing R/R ALL.
In the second segment, the panel explores actionable strategies to alleviate the burden on patients and families. Dr. Singh emphasizes the importance of cost-effective treatment protocols, while Dr. Dikshit highlights innovations in outpatient care models to reduce hospitalization frequency. Dr. Jain and Dr. Baveja further discuss the role of patient advocacy, insurance reforms, and government policies in bridging gaps in care. Their collective expertise provides a comprehensive roadmap to address systemic inefficiencies and improve the quality of life for R/R ALL patients.
Concluding on a hopeful note, the experts underscore the need for collaborative efforts between clinicians, researchers, and policymakers to drive sustainable change. The discussion not only raises awareness but also inspires actionable solutions to mitigate the economic and emotional toll of R/R ALL. Viewers are encouraged to watch the full video to gain deeper insights into this pressing issue and stay tuned for future discussions featuring these thought leaders in oncology and hematology.
See More Webinars @ Hidoc Webinars
1.
A novel test shows promise for finding cervical adenocarcinoma, which is difficult to find.
2.
Researchers publish action plan to address appendiceal cancer enigmas
3.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
4.
Underprescribed for Alcohol Use Disorder is pharmacotherapy.
5.
Cancer "Tidal Wave" Prediction: Not Cigarette-Based, Either! Wary Stories Regarding Cannabis and Cancer.
1.
Unveiling the Mystery of Echinocyte: A Closer Look at the Unique Red Blood Cell
2.
The Bloodstream Compass: A Comparative Clinical Review of Liquid Biopsy and AI in Predictive Oncology
3.
Exploring the Latest Advances in Hodgkin's Lymphoma Treatment
4.
Partial Gland Ablation in Prostate Cancer: Oncologic Outcomes in Intermediate-Risk Cases
5.
Optimizing Oncology Practice Revenue: Billing Software, Payer Trends, and Financial Navigation Tools
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
2.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
4.
A New Era in Managing Cancer-Associated Thrombosis
5.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation